Marburg virus disease: A summary for clinicians. (October 2020)

• Record Type: Journal Article
• Authors: Kortepeter, Mark G.; Dierberg, Kerry; Shenoy, Erica S.; Cieslak, Theodore J.
• Is Part Of: International journal of infectious diseases. Volume 99(2020)
• Page Start: 233
• Page End: 242
• Publication Date: 2020-10
• Subjects: Marburg virus -- Filovirus -- Ebola virus -- Antiviral therapy -- Antiviral countermeasure -- Vaccine -- Treatment; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Electronic journals; 616.9
• DOI: 10.1016/j.ijid.2020.07.042
• Languages: English
• ISSNs: 1201-9712

Abstract

Highlights: Marburg virus medical countermeasures are not as advanced as those for Ebola virus. No licensed medical countermeasures for Marburg virus currently exist. One monoclonal antibody has thus far been used in humans. Several promising vaccine platforms are being studied. Abstract: Objectives: This article summarizes the countermeasures for Marburg virus disease, focusing on pathogenesis, clinical features and diagnostics. There is an emphasis on therapies and vaccines that have demonstrated, through their evaluation in nonhuman primates (NHPs) and/or in humans, potential for use in an emergency situation. Methods: A standardized literature review was conducted on vaccines and treatments for Marburg virus disease, with a focus on human and nonhuman primate data published in the last five years. More detail on the methods that were used is summarized in a companion methods paper. Results: The study identified six treatments and four vaccine platforms that have demonstrated, through their efficacy in NHPs, potential benefit for treating or preventing infection in humans. Conclusion: Succinct summaries of Marburg countermeasures are provided to give the busy clinician a head start in reviewing the literature if faced with a patient with Marburg virus disease. Links to other authoritative sources of information are also provided.